Crescent Biopharma (CBIO) Accounts Payables (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Accounts Payables of $2.5 million for Q2 2026, up 54.25% year-over-year from $1.6 million in Q2 2025, and up 113.61% quarter-over-quarter from $1.2 million in Q1 2026.
Crescent Biopharma (CBIO) Accounts Payables (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Accounts Payables for 14 consecutive years, with $2.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Accounts Payables rose 54.25% year-over-year to $2.5 million; the TTM figure through Jun 2026 stood at $2.5 million (up 54.25% YoY), while the FY2025 annual figure was $10.0 million, up 9242.99% from the prior year.
- Accounts Payables grew to $2.5 million in Q2 2026 per CBIO's latest filing, from $1.2 million in the prior quarter.
- Across five years, Accounts Payables topped out at $10.0 million in Q4 2025 and bottomed at $104671.0 in Q1 2025.
- Historically, Accounts Payables has averaged $1.5 million across 5 years, with a median of $909439.0 in 2023.
- Annual changes were most pronounced in 2024 — Accounts Payables plunged 87.67% — and 2025, when it surged 9242.99%.
- Crescent Biopharma's Accounts Payables stood at $970191.0 in 2022, then dropped by 10.52% to $868115.0 in 2023, then slumped by 87.67% to $107000.0 in 2024, then soared by 9242.99% to $10.0 million in 2025, then sank by 74.57% to $2.5 million in 2026.
- Business Quant data shows CBIO's Accounts Payables at $2.5 million in Q2 2026, $1.2 million in Q1 2026, and $10.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.50 Bn | 131.65 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.10 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.59 Bn | 60.41 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 56.75 Bn | 51.62 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.80 Bn | 9.41 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 35.57 Mn |
| 10 | Crescent Biopharma | 1.07 Bn | 898.18 Mn | - | 2.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.54 Mn |
| Mar 31, 2026 | 1.19 Mn |
| Dec 31, 2025 | 10.00 Mn |
| Sep 30, 2025 | 2.56 Mn |
| Jun 30, 2025 | 1.65 Mn |
| Mar 31, 2025 | 104,671.00 |
| Dec 31, 2024 | 107,000.00 |
| Sep 30, 2024 | 581,794.00 |
| Jun 30, 2024 | 950,763.00 |
| Mar 31, 2024 | 755,534.00 |
| Dec 31, 2023 | 868,115.00 |
| Sep 30, 2023 | 329,885.00 |
| Jun 30, 2023 | 241,487.00 |
| Mar 31, 2023 | 480,151.00 |
| Dec 31, 2022 | 970,191.00 |
| Sep 30, 2022 | 852,125.00 |
| Jun 30, 2022 | 1.27 Mn |
| Mar 31, 2022 | 2.28 Mn |
| Dec 31, 2021 | 2.11 Mn |
| Sep 30, 2021 | 1.39 Mn |